Antiretroviral therapy uses combinations of medicines that target different stages of the HIV replication cycle. HIV depends on several viral enzymes and cellular processes to produce new copies of itself. By interfering with these processes, antiretroviral medicines can substantially reduce viral replication and help maintain immune system function.
The development of combination therapy has been an important milestone in HIV medicine. Using medicines with different mechanisms can improve viral suppression and reduce the likelihood that resistant viral strains will become dominant.
Key concepts include:
Understanding these mechanisms also helps researchers develop new therapeutic strategies and investigate why some viral strains become resistant to particular medicines.
HIV enters susceptible cells and uses its genetic material and viral enzymes to create new viral particles. Several antiretroviral drug classes interfere with this process at different points.
Entry and attachment inhibitors interfere with steps involved in HIV entering target cells. Reverse transcriptase inhibitors interfere with the viral enzyme responsible for converting HIV RNA into DNA. Integrase inhibitors target the integration of viral DNA into the host cell genome.
Protease inhibitors act later in the viral life cycle by interfering with the processing of viral proteins needed to produce mature infectious particles.
Important areas of research include:
Researchers continue studying these mechanisms to identify treatments that can be more durable, convenient, and effective against diverse HIV strains.
HIV research extends beyond controlling viral replication. Scientists are investigating approaches that could improve long term treatment, address resistance, simplify treatment schedules, and potentially achieve sustained remission without continuous therapy.
Long acting treatment approaches are an important research and clinical development area because they may reduce the need for frequent daily medication in appropriate circumstances. Other investigations focus on broadly neutralizing antibodies, immune based approaches, viral reservoirs, gene based strategies, and methods for targeting persistent HIV.
Research priorities include:
These areas demonstrate how HIV research continues to evolve from controlling viral replication toward addressing the biological factors that allow HIV to persist.
Antiretroviral therapy works by targeting critical stages of the HIV life cycle and reducing viral replication. Understanding these mechanisms provides a foundation for appreciating advances in HIV treatment and research. Continued investigation into drug resistance, long acting therapies, viral reservoirs, immune responses, and emerging therapeutic strategies may contribute to further progress in HIV medicine. This information is intended for educational purposes and should not replace guidance from qualified healthcare professionals.